Renalytix (
RENX · AIM · Health Care · mcap £39m · 5.3p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 28 Sep 26 | Result of General Meeting
LONDON and NEW YORK, 28 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that at the General Meeting (“GM”) held earlier today, all |
+0.0% | |
| 28 Sep 26 | Board change | Directorate Change
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that Julian Baines MBE has indicated his intention to stand down as Non-Executive Chair of Renalyti |
+0.0% |
| 25 Sep 26 | Investor Presentations
LONDON and NEW YORK, 25 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that it will host a live online investor presentation next |
+0.0% | |
| 16 Sep 26 | Board change | Additional CEO Share Purchase
LONDON and NEW YORK, 16 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 11 September and 15 September 2026 James McCullough |
+5.0% |
| 14 Sep 26 | New Accounting Ref Date
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that it has resolved to change the Company's accounting reference date. |
+1.6% | |
| 11 Sep 26 | Board change | CEO Share Purchase
LONDON and NEW YORK, 11 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 8 September 2026 and 9 September 2026 James McCullo |
+12.5% |
| 08 Sep 26 | Capital Access Window - Renalytix Plc | +30.1% | |
| 08 Sep 26 | Fundraise | Result of WRAP Retail Offer
Renalytix is pleased to announce, further to its announcement of 3 September 2026, the completion of the WRAP Retail Offer at an issue price of £0.06 per Ordinary Share (the "Placing Price"). |
+30.1% |
| 03 Sep 26 | Offer | WRAP Retail Offer for up to £1,000,000
Renalytix is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £1,000,000 (the "WRAP Retail Offer") through the issue of new ordinary shares of £0.0025 each in the capi |
+0.0% |
| 03 Sep 26 | Fundraise | Result of Fundraise
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, confirms that, further to the Company's announcement released at 7.01 a.m. on 1 September 2026 (RNS Number: 8 |
+0.0% |
| 01 Sep 26 | Capital Access Window - Renalytix plc | +0.0% | |
| 01 Sep 26 | Fundraise | Proposed Fundraise
596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("UK MAR"). |
+0.0% |
| 01 Sep 26 | Collaboration with Quest Diagnostics
Collaboration with Quest Diagnostics to expand kidneyintelX.dkdTM testing in the United States |
+0.0% | |
| 24 Aug 26 | AIM Rule 17 Disclosure
LONDON and NEW YORK, 24 August 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, provides the following update pursuant to Rule 17 and Schedule 2 (g) (v |
+10.4% | |
| 30 Jun 26 | Real world evidence study data published
· Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk prognosis, improvements in kidney function, increases in guideline-directed therapy uptake, and measurable reduction in indivi |
+21.1% | |
| 22 Apr 26 | Key milestones achieved for kidneyintelX.dkd
Key regulatory milestones achieved in support of scaling of kidneyintelX.dkd |
+0.0% | |
| 26 Mar 26 | Results | Half-year Results
LONDON and NEW YORK, 26 March, 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd , is the only FDA-approved and Medicare-reimbursed prognostic test |
+6.8% |
| 13 Feb 26 | Board change | Further CEO Share Purchase
LONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test |
+1.9% |
| 12 Feb 26 | Director dealing | Director/PDMR Share Purchase
LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test |
−1.8% |
| 12 Feb 26 | Board change | CEO Share Purchase
LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test |
−1.8% |
| 11 Feb 26 | Trading update | H1 Trading update
LONDON and NEW YORK, 11 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test |
−26.3% |
| 12 Jan 26 | Three kidneyintelX.dkd Clinical Integrations
LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support e |
+0.0% | |
| 09 Dec 25 | AGM Statement
LONDON and NEW YORK, 9 December 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support e |
−7.4% | |
| 25 Nov 25 | Plan to Implement ADS Ratio Change
Renalytix Announces Plan to Implement ADS Ratio Change |
+0.0% | |
| 12 Nov 25 | Pivotal kidneyintelX.dkd data published
Pivotal kidneyintelX.dkd data published in Diabetes Care Journal of the American Diabetes Association |
−5.5% | |
| 03 Nov 25 | Results | Audited Full Year Fiscal 2025 Results
LONDON and NEW YORK, 3 November 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support e |
−10.5% |
| 27 Oct 25 | Confirmation of receipt of £860k R&D tax credits
Confirmation of receipt of £860k of R&D tax credits |
+1.4% | |
| 10 Oct 25 | $4m balance sheet improvement with bond conversion
The conversion of the Convertible Bonds will provide a significant improvement to Renalytix's balance sheet, improving the Company's net asset position by approximately $4m and saving up to $1.4m in accrued interest over |
+2.8% |
Company filings. Not investment advice.